Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease
Status:
Completed
Trial end date:
2019-11-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of high-dose human
Immunoglobulin G Intravenous (IGIV) 10% in subjects with Kawasaki diseases (KD).
Phase:
Phase 4
Details
Lead Sponsor:
Green Cross Corporation
Treatments:
Antibodies Aspirin Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous